Gastro-resistant microparticles as an oral cholera vaccine approach

Marta Pastor Navarro
Faculty of Pharmacy. University of the Basque Country
Personas encargadas de la dirección:
Jose Luis Pedraz and Amaia Esquisabel

Gastro resistant microparticles as an oral cholera vaccine approachGastroresistant microparticles as a strategy for an oral cholera vaccineAlthough cholera disease and its causative agent, Vibrio cholerae, have been known since the nineteenth century, cholera remains a disease with a high incidence today, especially in places where minimum hygiene criteria are not met. In this context, disease prevention is a key issue. Among the strategies for prevention and control of the disease, the implementation of sanitation and vaccination are included. Since 1999, the World Health Organization (WHO) has recommended oral cholera vaccine for use in certain endemic regions or emergency situations. Following the re-analysis of the clinical trial in Bangladesh with an oral cholera vaccine, it was found that the fact that part of the population had been vaccinated provided community protection. That is why the development of an effective and safe cholera vaccine would be a further step in controlling outbreaks of the disease. Based on the results of the in vivo, stability and toxicity experiments, Vibrio cholerae microencapsulated in Eudragit® L30 D-55, and especially when alginate is added, gives rise to a safe, effective and cold chain-free vaccine. -The results of the in vitro study of Aquacoat® CPD microparticles with and without alginate showed that the particles obtained by the Vibrio cholerae microencapsulated in the Eudragit® L30 D-55 were very effective. The release profile exhibited gastroresistant properties releasing 30% of the bacteria at 24 hours. The results of the in vivo study of Aquacoat® CPD microparticles revealed that microparticles with and without alginate and in doses of 30 mg are capable of inducing an immune response similar to Vibrio cholerae.

Enlace con información adicional: